Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

In the phase 2/3 DEVOTE study, a higher dose of nusinersen met its primary end point at 6 months, achieving a statistically significant improvement in motor function among treatment-naïve symptomatic infants with SMA.

FDA Accepts sNDA for Higher Dosing Regimen of Nusinersen for Spinal Muscular Atrophy

Videos

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program provided commentary on patient selection and personalized treatment approaches when using neuromodulation devices for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Personalizing Neuromodulation and Tailoring Approaches for Lennox-Gastaut Syndrome: Depobam Samanta, MD, MS, FAAP, FAES

Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.

Insights From AES 2024: Advancements and Challenges in Epilepsy Care

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

Implications of New Multiple Sclerosis Criteria on Overlapping Autoimmune Conditions: Joseph Kuchling, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Professor, department of neurology, NYU Langone Health Center, and codirector, Epilepsy Clinical Trials, NYU Langone, Comprehensive Epilepsy Center; founder/director, Epilepsy Study Consortium.

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

NeuroVoices: Jacqueline A. French, MD, on Leveraging Neurostimulators to Advance Epilepsy Drug Development

The study highlighted tofersen's potential to slow ALS progression in patients with SOD1 mutations, showing reduced neurofilament levels, functional stabilization, and improved muscle strength, despite mild to moderate adverse events.

Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

In the last year, the FDA has approved a number of drugs for a variety of neurologic disorders. Here are 8 of the most recent.

Slideshows

The FDA has recently approved a number of drugs for a variety of neurologic disorders, including Parkinson's disease and MS. Here are 8 of the newest.

8 New FDA-Approved Neurology Drugs